SCHEMBL17217581

SCHEMBL17217581

N#Cc1cccc([C]=NOCc2ccc(Cl)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX4 Q96LA9 2/20 0.46
▸ NPC1 O15118 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ CCR5 P51681 1/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ GAA P10253 1/20 0.40
▸ VNN1 O95497 1/20 0.39
▸ GRM5 P41594 2/20 0.39
▸ CNR1 P21554 5/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ CNR2 P34972 3/20 0.37
▸ MAOB P27338 2/20 0.37
▸ MAOA P21397 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GLA P06280 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ PTGER1 P34995 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17217578 1.00 MRGPRX4 (0.46) MRGPRX4NPC1RAB9ACCR5SMN1; SMN2
SCHEMBL17218720 0.90 NPC1 (0.49) MRGPRX4NPC1RAB9ASMN1; SMN2GAA
SCHEMBL17218724 0.90 NPC1 (0.49) MRGPRX4NPC1RAB9ASMN1; SMN2GAA
SCHEMBL17219555 0.89 MRGPRX4 (0.52) MRGPRX4VNN1GRM5CNR1SLC6A4
SCHEMBL17219554 0.89 MRGPRX4 (0.52) MRGPRX4VNN1GRM5CNR1SLC6A4
SCHEMBL17216854 0.87 NPC1 (0.45) MRGPRX4NPC1RAB9ASMN1; SMN2GAA
SCHEMBL17216855 0.87 NPC1 (0.45) MRGPRX4NPC1RAB9ASMN1; SMN2GAA
SCHEMBL17218968 0.87 MRGPRX4 (0.54) MRGPRX4CCR5GRM5CNR1SLC6A4
SCHEMBL17218965 0.87 MRGPRX4 (0.54) MRGPRX4CCR5GRM5CNR1SLC6A4
SCHEMBL17218163 0.87 MAOB (0.42) MRGPRX4L3MBTL1MAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 MRGPRX4 1822/4885NPC1 1841/4885RAB9A 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback